Physician profile
Leonor Santos
NPI 1902914815
$4,914.99
in general payments reported to CMS, 2019-2025
28 companies · $1,054 in 2025
The $1,054 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $932 · 2020: $363 · 2021: $516 · 2022: $580 · 2023: $751 · 2024: $718 · 2025: $1,054.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,523.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,126.24 | 2019-2025 | Linzess, Viberzi, Creon |
| Nestle Healthcare Nutrition INC. | $398.79 | 2020-2023 | |
| Vivus LLC | $391.77 | 2019-2025 | Pancreaze |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $342.85 | 2019-2025 | Xifaxan, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $200.13 | 2019-2025 | Entyvio, Eohilia |
| Ethicon US, LLC | $150.00 | 2025 | Echelon Endopath |
| Aimmune Therapeutics, INC. | $146.47 | 2025 | Zenpep |
| Allergan, INC. | $137.74 | 2019 | |
| Madrigal Pharmaceuticals | $129.01 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $128.74 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $121.44 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $78.37 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $75.83 | 2023-2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $72.70 | 2019-2025 | Ocaliva |
| Genzyme Corporation | $70.82 | 2022-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $68.67 | 2024-2025 | Vegzelma, Zymfentra |
| Braintree Laboratories, INC. | $42.90 | 2020-2021 | |
| Celgene Corporation | $41.15 | 2023-2024 | Zeposia |
| Romark Laboratories, Lc | $28.69 | 2019 | |
| Merck Sharp & Dohme LLC | $27.86 | 2019 | |
| Gilead Sciences, INC. | $21.43 | 2021 | |
| Redhill Biopharma INC. | $20.19 | 2022 | |
| Heron Therapeutics, INC. | $19.56 | 2022 | |
| Ironwood Pharmaceuticals, INC | $18.53 | 2019 | |
| Endo Pharmaceuticals INC. | $15.30 | 2020 | |
| Ucb, INC. | $13.64 | 2019 | |
| Axonics, INC. | $13.53 | 2024 | Axonics |
| Biodelivery Sciences International, INC. | $12.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonor Santos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.